OMCL Quote, Financials, Valuation and Earnings

CareCloud, Inc. has a net margin of -0.65% compared to Omnicell, Inc.'s net margin of 9.85%. Omnicell, Inc.'s return on equity of 0.17% beat CareCloud, Inc.'s return on equity of 21.2%.

Omnicell, Inc. has a consensus price target of $57.43, signalling upside risk potential of 48.66%. On the other hand CareCloud, Inc. has an analysts' consensus of $6.31 which suggests that it could grow by 152.5%. Given that CareCloud, Inc. has higher upside potential than Omnicell, Inc., analysts believe CareCloud, Inc. is more attractive than Omnicell, Inc..

Omnicell, Inc. has a beta of 0.776, which suggesting that the stock is 22.402% less volatile than S&P 500. In comparison CareCloud, Inc. has a beta of 2.051, suggesting its more volatile than the S&P 500 by 105.142%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CareCloud, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. CareCloud, Inc. pays out -- of its earnings as a dividend.

Omnicell, Inc. quarterly revenues are $314M, which are larger than CareCloud, Inc. quarterly revenues of $31.1M. Omnicell, Inc.'s net income of -$2M is lower than CareCloud, Inc.'s net income of $3.1M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 894.21x while CareCloud, Inc.'s PE ratio is 61.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.50x versus 0.68x for CareCloud, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health, Inc. has a net margin of -0.65% compared to Omnicell, Inc.'s net margin of -4.35%. Omnicell, Inc.'s return on equity of 0.17% beat Evolent Health, Inc.'s return on equity of -13.6%.

Omnicell, Inc. has a consensus price target of $57.43, signalling upside risk potential of 48.66%. On the other hand Evolent Health, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 206.86%. Given that Evolent Health, Inc. has higher upside potential than Omnicell, Inc., analysts believe Evolent Health, Inc. is more attractive than Omnicell, Inc..

Omnicell, Inc. has a beta of 0.776, which suggesting that the stock is 22.402% less volatile than S&P 500. In comparison Evolent Health, Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.123%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. Evolent Health, Inc. pays out 32.59% of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omnicell, Inc. quarterly revenues are $314M, which are smaller than Evolent Health, Inc. quarterly revenues of $479.5M. Omnicell, Inc.'s net income of -$2M is higher than Evolent Health, Inc.'s net income of -$20.9M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 894.21x while Evolent Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.50x versus 0.16x for Evolent Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of -0.65% compared to Omnicell, Inc.'s net margin of 14.05%. Omnicell, Inc.'s return on equity of 0.17% beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.

Omnicell, Inc. has a consensus price target of $57.43, signalling upside risk potential of 48.66%. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Omnicell, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Omnicell, Inc. is more attractive than Pacific Health Care Organization, Inc..

Omnicell, Inc. has a beta of 0.776, which suggesting that the stock is 22.402% less volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Omnicell, Inc. pays -- of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.

Omnicell, Inc. quarterly revenues are $314M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Omnicell, Inc.'s net income of -$2M is lower than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, Omnicell, Inc.'s price-to-earnings ratio is 894.21x while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.50x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

10X Genomics, Inc. has a net margin of -0.65% compared to Omnicell, Inc.'s net margin of -9.79%. Omnicell, Inc.'s return on equity of 0.17% beat 10X Genomics, Inc.'s return on equity of -5.77%.

Omnicell, Inc. has a consensus price target of $57.43, signalling upside risk potential of 48.66%. On the other hand 10X Genomics, Inc. has an analysts' consensus of $19.36 which suggests that it could grow by 0.87%. Given that Omnicell, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Omnicell, Inc. is more attractive than 10X Genomics, Inc..

Omnicell, Inc. has a beta of 0.776, which suggesting that the stock is 22.402% less volatile than S&P 500. In comparison 10X Genomics, Inc. has a beta of 2.244, suggesting its more volatile than the S&P 500 by 124.385%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 10X Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. 10X Genomics, Inc. pays out -- of its earnings as a dividend.

Omnicell, Inc. quarterly revenues are $314M, which are larger than 10X Genomics, Inc. quarterly revenues of $166M. Omnicell, Inc.'s net income of -$2M is higher than 10X Genomics, Inc.'s net income of -$16.3M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 894.21x while 10X Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.50x versus 3.73x for 10X Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.